Stockscreener 앱 받기
44.58
0.70%
-0.45
Veracyte Inc 주식(VCYT)의 최신 뉴스
Here's why Veracyte (VCYT) is a strong momentum stock - MSN
Veracyte Stock Surges 65.8% in a Year: What's Driving the Rally? - TradingView
Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago - Yahoo Finance UK
Assessing Veracyte (VCYT) Valuation After Phase III Success For Prosigna And Decipher Cancer Tests - Yahoo Finance
Veracyte director Robert S Epstein sells $440,129 in company stock - Investing.com India
Insider Sell: Robert Epstein Sells 10,000 Shares of Veracyte Inc (VCYT) - GuruFocus
Veracyte director Robert S Epstein sells $440,129 in company stock By Investing.com - Investing.com Australia
Veracyte Insider Sold Shares Worth $440,129, According to a Recent SEC Filing - Moomoo
Veracyte (VCYT) director sells 10,000-share block under 10b5-1 plan - Stock Titan
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings - Business Wire
VCYT Stock Price, Quote & Chart | VERACYTE INC (NASDAQ:VCYT) - ChartMill
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer - Business Wire
Kevin Haas Named Chief Development and Technology Officer at Veracyte - Medical Product Outsourcing
Veracyte Jumps 7.8% Amid Sector-Wide Rally - AlphaStreet
[144] VERACYTE, INC. SEC Filing - Stock Titan
Why Veracyte (VCYT) Is Up 5.4% After Medicare Backs Its TrueMRD Bladder Cancer Test - Sahm
Veracyte to Participate in Upcoming June 2026 Investor Conferences - BioSpace
Veracyte to Participate in Upcoming Investor Conferences - 01net
Veracyte stock (US92347M1009): diagnostics specialist back in the spotlight after new data and index - AD HOC NEWS
CCORF Maintains Veracyte(VCYT.US) With Hold Rating, Maintains Target Price $42 - Moomoo
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer - marketscreener.com
Why Veracyte (VCYT) is a Top Growth Stock for the Long-Term - Yahoo Finance
A Look At Veracyte (VCYT) Valuation After Medicare Coverage For TrueMRD Cancer Monitoring Test - Sahm
Veracyte stock (US92347M1009): earnings momentum and cancer diagnostics focus - AD HOC NEWS
Veracyte Secures Medicare Coverage for Bladder Cancer Monitoring Test - Moomoo
Veracyte (VCYT) Gains CMS Coverage for TrueMRD Monitoring Test - GuruFocus
Veracyte Gains Medicare Coverage for Muscle-Invasive Bladder Cancer Recurrence Monitoring Test - Contract Pharma
Veracyte’s TrueMRD Monitoring Test receives coverage from CMS - TipRanks
Veracyte’s bladder cancer test receives Medicare coverage By Investing.com - Investing.com South Africa
Veracyte’s bladder cancer test receives Medicare coverage - Investing.com
Veracyte secures Medicare coverage for Truemrd monitoring test in muscle-invasive bladder cancer - marketscreener.com
Veracyte Secures Medicare Coverage For Truemrd Monitoring Test In Muscle-Invasive Bladder Cancer - TradingView
Shareholders Will Be Pleased With The Quality of Veracyte's (NASDAQ:VCYT) Earnings - simplywall.st
Statutory Profit Doesn't Reflect How Good Veracyte's (NASDAQ:VCYT) Earnings Are - Yahoo Finance
Veracyte Inc (VCYT) Shares Fall 3.3% -- What GF Score of 82 Tells Investors - GuruFocus
Artisan Partners (NYSE: VCYT) reports 5.50M shares, 6.9% stake in Veracyte - Stock Titan
Morgan Stanley Initiates Veracyte(VCYT.US) With Sell Rating, Announces Target Price $39.7 - Moomoo
State Street (VCYT) discloses 5.04M-share, 6.3% holding in Veracyte - Stock Titan
State of New Jersey Common Pension Fund D Invests $1.13 Million in Veracyte, Inc. $VCYT - MarketBeat
Veracyte | 4: Statement of changes in beneficial ownership of securities-Officer Stapley Marc - Moomoo
Why Veracyte Stock Is Skyrocketing Higher This Week - AOL.com
Veracyte (VCYT) Is Up 23.8% After Raising 2026 Guidance And Expanding Decipher Cancer Studies - simplywall.st
Veracyte (VCYT) Q1 2026 Earnings: Revenue Up 21%, EPS Quadruples, Shares Climb 23%News and Statistics - IndexBox
Veracyte, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:VCYT) 2026-05-08 - Seeking Alpha
Insider Sell: Annie Mcguire Sells 10,204 Shares of Veracyte Inc (VCYT) - GuruFocus
Veracyte SVP McGuire sells $398,211 in shares By Investing.com - Investing.com South Africa
Veracyte SVP McGuire sells $398,211 in shares - Investing.com
Veracyte (VCYT) general counsel sells 10,204 shares in 10b5-1 plan - Stock Titan
0.23%
0.65%
자본화:
|
볼륨(24시간):